CRO Service
TTY Oncology Translational Research Center comes with abundant experiences in bioassay development and is capable of using professional project management model to speed up pre-clinical drug development. It provides clients with the most appropriate and efficient R&D energy to satisfy the needs for bio-contract tests from both domestic and offshore respective parties while supplementing early-stage bio-research industry chain gap and enhancing industry efficiency.
TTY Oncology Translational Research Center qualifies for TAF ISO/IEC17025 certifications. It owns SPF animal facilities and BSL-2 laboratory and is equipped with advanced molecular biology, cellular biology and pathology research facilities. The following service items can be provided in accordance with client’s needs：
Biomarker assay
Biomarker assay
- Fluorescent in situ hybridization, FISH
- Flow Cytometry
- Immunohistochemistry, IHC
- Immunofluorescence, IF
- Protein expression assay
- Receptor tyrosine kinase array
- Immune cell subgroup analysis
- Stable cell line generation
- Comet assay
- Cell apoptosis assay
- Cell anti-proliferation assay
- Cell migration assay
- Cell invasion assay
- Cell cytotoxicity assay
- Cell cycle analysis
- Tumor model establishment: breast cancer, hepatoma, gastric cancer, colon cancer, oral cancer, uterine sarcom, ovarian cancer , epidermoid sarcoma, lung cancer, endometrial cancer, B cell lymphoma, pancreatic cancer, bile tract cancer and peritoneal metastatic carcinoma.
- Hyperuricemia
- Acute renal failure
- Chronic renal failure
- Hyperthermia chemotherapy
- Animal Models of Infection
- Customized disease model establishment
- Toxicity studies
- Efficacy studies
- MoA studies
- Animal pharmacokinetics and biodistribution
- Near-IR in vivo imaging system
- H&E staining
- ELISA
- Enzyme-linked immunospot assay, ELISpot
- Antibody-antigen binding assay
- Fc gamma receptor binding assay
- FcRn binding assay
- Gene construction
- qPCR
- Viral production
- CFU assay
Please contact us for other customized services.
Scope of accreditation to TAF ISO/IEC 17025:
- Adhesion cell cytotoxicity test
- Evaluating drug therapeutic effect by mice subcutaneous solid tumor model
- Mice subcutaneous solid tumor model set up
- Paraffin section H&E stain
- IHC stain
- Identification and characterization of DNA (FISH)
Instruments and equipments:
- Leica ST5010 Autostainer
- Nikon Eclipse 80i Digital Imaging Head Fluorescence Microscope
- Olympus IX71 Inverted Microscope
- VisualSonics Vevo-770 ultrasound
- LI-COR Pearl Small Animal Imaging System
- Mindray BC-2800 Auto Hematology Analyzer
- BD FACSCanto II flow cytometry
- CFX Connect™ Real-Time PCR Detection System
- GloMax® Discover Multimode Microplate Reader
- Optima XE, Ultracentrifuge
Translational medicine is an inter-field science connecting basic research and clinical application. It combines efficient 2-way verification methods with the discovery of disease biomarker or drug candidate from basic research to ultimately become new methods for diagnosis and treatment.
TTY Translation Research Center was established in 2007 and has a professional R&D project team. We are your best partner for the development of early-stage new drugs. We have an ISO/IEC 17025 certified testing laboratory, a Biosafety Level 2 facility, and a specific pathogen-free animal room. We focus on early new drug screening, verification, evaluation, and in-licensing to develop. Using advanced translational research methods, we are committed to developing innovative drugs that can meet medical unmet needs and improve the quality of human life, with a view to becoming an innovative leader in pharmaceutical and healthcare industry in Asia.
TTY Translation Research Center was established in 2007 and has a professional R&D project team. We are your best partner for the development of early-stage new drugs. We have an ISO/IEC 17025 certified testing laboratory, a Biosafety Level 2 facility, and a specific pathogen-free animal room. We focus on early new drug screening, verification, evaluation, and in-licensing to develop. Using advanced translational research methods, we are committed to developing innovative drugs that can meet medical unmet needs and improve the quality of human life, with a view to becoming an innovative leader in pharmaceutical and healthcare industry in Asia.
